RPRX Repros Therapeutics Inc.

0.46
+0.07  (18%)
Previous Close 0.39
Open 0.41
Price To book 6.39
Market Cap 12.30M
Shares 26,732,000
Volume 1,636,302
Short Ratio 3.47
Av. Daily Volume 273,719

SEC filingsSee all SEC filings

  1. 8-K - Current report 17916166
  2. 8-K - Current report 17881748
  3. 8-K - Current report 17860934
  4. 424B5 - Prospectus [Rule 424(b)(5)] 17855292
  5. 424B5 - Prospectus [Rule 424(b)(5)] 17853413

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released November 14, 2016.
Proellex
Uterine fibroids (vaginal treatment)
Phase 2 data released September 2016. Announced December 19, 2016 that a meeting with the FDA has been requested - likely during 1H 2017.
Proellex
Endometriosis
CRL December 1 2015. Phase 2 6-month data released August 2016
Enclomiphene
Secondary hypogonadism
Phase 2b data released November 14, 2016. Noted January 30, 2017 that an end of Phase 2 meeting scheduled with FDA before the end of April, 2017. However, company noted April 10, 2017 that they meeting was in fact a Type C Guidance Meeting rather than an end of Phase 2 Type B meeting. Partial clinical hold remains in place.
Proellex
Uterine fibroids (oral treatment)

SEC Filings

  1. 8-K - Current report 17916166
  2. 8-K - Current report 17881748
  3. 8-K - Current report 17860934
  4. 424B5 - Prospectus [Rule 424(b)(5)] 17855292
  5. 424B5 - Prospectus [Rule 424(b)(5)] 17853413
  6. 8-K - Current report 17852450
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 17826774
  8. 8-K - Current report 17826292
  9. 8-K - Current report 17802909
  10. 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] 17795571